Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

In patients with unresectable liver metastases from colorectal cancer (CRCLM), systemic doublet or triplet chemotherapy and targeted therapy is considered a standard first-line treatment. Hepatic arterial infusion of oxaliplatin (HAI-ox) generates a high response rate, but this still needs to be con...

Full description

Saved in:
Bibliographic Details
Published in:Digestive and liver disease 2022-03, Vol.54 (3), p.324-330
Main Authors: Pernot, Simon, Pellerin, Olivier, Mineur, Laurent, Monterymard, Carole, Smith, Denis, Lapuyade, Bruno, Gallois, Claire, Khemissa Akouz, Faiza, De Baere, Thierry, Tougeron, David, Thirot-Bidault, Anne, Audemar, Franck, Simon, Mireille, Lecaille, Cedric, Louafi, Sami, Lepage, Come, Ducreux, Michel, Taieb, Julien
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Bevacizumab - administration & dosage
Colorectal neoplasm
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - pathology
Fluorouracil - administration & dosage
Hepatic arterial infusion
Hepatic Artery
Humans
Infusions, Intra-Arterial
Leucovorin - administration & dosage
Liver metastases
Liver Neoplasms - drug therapy
Liver Neoplasms - secondary
Organoplatinum Compounds - administration & dosage
Oxaliplatin - administration & dosage
Randomized controlled trial
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In patients with unresectable liver metastases from colorectal cancer (CRCLM), systemic doublet or triplet chemotherapy and targeted therapy is considered a standard first-line treatment. Hepatic arterial infusion of oxaliplatin (HAI-ox) generates a high response rate, but this still needs to be confirmed in a randomized trial. We incorporated HAI-ox in doublet or triplet + targeted therapy to validate its efficacy. The OSCAR study is an ongoing randomized phase III trial comparing FOLFOX + targeted therapy according to RAS status, or FOLFOXIRI + bevacizumab in patients eligible for triplet therapy, with the same regimen but with HAI-ox instead of IV-ox as the first-line treatment for CRCLM. Main eligibility criteria are colorectal cancer, unresectable liver metastasis, no extra-hepatic metastases except pulmonary nodules if ≤3 and
ISSN:1590-8658
1878-3562
DOI:10.1016/j.dld.2021.12.012